O	0	11	Prospective
O	12	22	comparison
O	23	25	of
B-intervention	26	33	Sapylin
I-intervention	34	37	and
I-intervention	38	45	Avitene
O	46	49	for
O	50	58	reducing
B-condition	59	66	hydrops
O	67	72	after
O	73	81	axillary
O	82	97	lymphadenectomy
O	98	100	in
O	101	107	breast
O	108	114	cancer
O	115	123	patients
O	123	124	.

O	125	129	This
O	130	135	study
O	136	144	compared
O	145	148	the
O	149	157	efficacy
O	158	160	of
O	161	168	Sapylin
O	169	172	and
O	173	180	Avitene
O	181	183	in
O	184	192	reducing
O	193	206	postoperative
O	207	215	axillary
O	216	222	seroma
O	223	232	formation
O	233	236	and
O	237	245	effusion
O	246	250	when
O	251	258	applied
O	259	268	topically
O	269	274	after
O	275	283	axillary
O	284	299	lymphadenectomy
O	299	300	.

O	301	302	A
O	303	308	total
O	309	311	of
B-total-participants	312	315	224
O	316	324	patients
O	325	329	were
O	330	338	randomly
O	339	346	divided
O	347	351	into
O	352	353	a
O	354	361	Sapylin
O	362	371	treatment
O	372	377	group
O	378	379	(
O	379	382	STG
O	382	383	)
O	383	384	,
O	385	387	an
O	388	395	Avitene
O	396	405	treatment
O	406	411	group
O	411	412	,
O	413	416	and
O	417	418	a
B-control	419	426	control
I-control	427	432	group
O	433	434	(
O	434	436	CG
O	436	437	)
O	437	438	.

O	439	442	All
O	443	451	patients
O	452	461	underwent
O	462	470	axillary
O	471	486	lymphadenectomy
O	487	490	and
O	491	495	were
O	496	503	treated
O	504	510	during
O	511	518	surgery
O	519	523	with
O	524	531	Sapylin
O	531	532	,
O	533	540	Avitene
O	540	541	,
O	542	544	or
O	545	552	neither
O	553	562	according
O	563	565	to
O	566	571	their
O	572	577	group
O	578	588	assignment
O	588	589	.

O	590	593	The
O	594	602	duration
O	603	606	and
O	607	613	amount
O	614	616	of
O	617	630	postoperative
O	631	639	drainage
O	639	640	,
O	641	643	as
O	644	648	well
O	649	651	as
O	652	655	the
O	656	666	occurrence
O	667	669	of
O	670	677	seromas
O	678	682	were
O	683	691	recorded
O	691	692	.

O	693	701	Outcomes
O	702	706	were
O	707	715	compared
O	716	718	by
O	719	722	one
O	722	723	-
O	723	726	way
O	727	735	analysis
O	736	738	of
O	739	747	variance
O	748	751	and
O	752	755	chi
O	755	756	-
O	756	762	square
O	763	768	tests
O	768	769	.

O	770	778	Baseline
O	779	786	patient
O	787	791	data
O	791	792	,
O	793	802	including
O	803	806	age
O	806	807	,
O	808	812	body
O	813	817	mass
O	818	823	index
O	823	824	,
O	825	832	history
O	833	835	of
O	836	847	neoadjuvant
O	848	860	chemotherapy
O	860	861	,
O	862	866	type
O	867	869	of
O	870	877	surgery
O	877	878	,
O	879	885	number
O	886	888	of
O	889	897	resected
O	898	903	lymph
O	904	909	nodes
O	909	910	,
O	911	914	and
O	915	921	number
O	922	924	of
O	925	933	positive
O	934	944	metastases
O	945	948	did
O	949	952	not
O	953	959	differ
O	960	965	among
O	966	969	the
O	970	975	three
O	976	982	groups
O	982	983	.

O	984	992	Patients
O	993	995	in
O	996	1000	both
O	1001	1004	the
O	1005	1008	STG
O	1009	1012	and
O	1013	1016	the
O	1017	1024	Avitene
O	1025	1034	treatment
O	1035	1040	group
O	1041	1052	experienced
O	1053	1066	significantly
O	1067	1072	fewer
B-outcome	1073	1077	days
I-outcome	1078	1080	of
I-outcome	1081	1089	drainage
O	1090	1094	than
O	1095	1100	those
O	1101	1103	in
O	1104	1107	the
O	1108	1110	CG
O	1110	1111	;
O	1112	1117	there
O	1118	1121	was
O	1122	1124	no
O	1125	1136	significant
O	1137	1147	difference
O	1148	1150	in
B-outcome	1151	1159	drainage
I-outcome	1160	1164	tube
I-outcome	1165	1174	retention
I-outcome	1175	1179	time
O	1180	1187	between
O	1188	1191	the
O	1192	1195	two
O	1196	1203	treated
O	1204	1210	groups
O	1210	1211	.

O	1212	1215	The
O	1216	1219	STG
O	1220	1231	experienced
O	1232	1245	significantly
O	1246	1250	less
B-outcome	1251	1259	drainage
I-outcome	1260	1266	volume
O	1267	1271	than
O	1272	1275	the
O	1276	1278	CG
O	1278	1279	.

O	1280	1285	Fewer
O	1286	1294	patients
O	1295	1297	in
O	1298	1302	both
O	1303	1312	treatment
O	1313	1319	groups
B-outcome	1320	1328	required
I-outcome	1329	1335	seroma
I-outcome	1336	1345	treatment
I-outcome	1346	1348	or
I-outcome	1349	1360	experienced
I-outcome	1361	1374	complications
O	1375	1383	compared
O	1384	1388	with
O	1389	1391	CG
O	1392	1400	patients
O	1400	1401	.

O	1402	1406	Both
O	1407	1414	Sapylin
O	1415	1418	and
O	1419	1426	Avitene
O	1427	1438	effectively
O	1439	1446	reduced
O	1447	1460	postoperative
O	1461	1473	subcutaneous
O	1474	1479	fluid
O	1480	1492	accumulation
O	1493	1498	after
O	1499	1507	axillary
O	1508	1523	lymphadenectomy
O	1523	1524	.

O	1525	1530	These
O	1531	1541	treatments
O	1542	1545	may
O	1546	1548	be
O	1549	1561	particularly
O	1562	1568	useful
O	1569	1572	for
O	1573	1579	breast
O	1580	1586	cancer
O	1587	1595	patients
O	1596	1598	at
O	1599	1603	high
O	1604	1608	risk
O	1609	1611	of
O	1612	1618	seroma
O	1619	1628	formation
O	1628	1629	,
O	1630	1640	especially
O	1641	1646	those
O	1647	1651	with
O	1652	1664	hypertension
O	1664	1665	,
O	1666	1674	diabetes
O	1675	1683	mellitus
O	1683	1684	,
O	1685	1687	or
O	1688	1689	a
O	1690	1694	high
O	1695	1699	body
O	1700	1704	mass
O	1705	1710	index
O	1711	1714	who
O	1715	1722	undergo
O	1723	1731	axillary
O	1732	1747	lymphadenectomy
O	1747	1748	.
